Skip to main content

Table 4 Summary of adverse events in the enrolled patients

From: Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

  Standard care (n = 12) Interferon (n = 44) LPV/r plus interferon (n = 67) Total patients (n = 123) P-value
Any event      
 Nausea 0 1 (2.27) 5 (7.46) 6 (4.88) 0.33
 Diarrhea 0 4 (9.09) 11 (16.42) 15 (12.20) 0.20
 Rash 0 2 (4.55) 2 (2.99) 4 (3.25) 0.72
 Leukopenia 0 8 (18.18) 8 (11.94) 16 (13.01) 0.23
 Neutropenia 0 6 (13.64) 6 (8.96) 12 (9.76) 0.35
 Anemia 1 (8.33) 1 (2.27) 3 (4.48) 6 (4.88) 0.12
 Thrombocytopenia 0 2 (4.55) 1 (1.49) 6 (4.88) 0.25
 Increased creatinine 0 2 (4.55) 1 (1.49) 3 (2.44) 0.50
 Increased aminotransferase 0 2 (4.55) 1 (1.49) 3 (2.44) 0.50
 Increased bilirubin 1 (8.33) 2 (4.55) 9 (13.43) 12 (9.76) 0.30
 Increased creatine kinase 0 7 (15.91) 14 (20.90) 21 (17.07) 0.20
  1. Data are n (%)